Ewing’s Sarcoma | A Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Jul 9, 2018--Technavio has announced their latest pipeline analysis report on the market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Ewing’s sarcoma.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180709005771/en/
Technavio has published a new report on the drug development pipeline for Ewing’s sarcoma, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Ewing’s sarcoma - market overview
Ewing’s sarcoma is a type of cancer that affects soft tissue and bones. It is a rare and malignant, round, blue cell tumor. Ewing’s sarcoma is common in pediatric patients, teenagers, and young adults. The most commonly affected areas are long bones, including the pelvic bone, femur, ribs, and collarbone.
According to a senior analyst at Technavio for research on oncology , “Ewing’s sarcoma is known to spread rapidly, which makes it difficult to treat patients and increases the recovery period. The probability of redevelopment of Ewing’s sarcoma after the completion of the treatment is high, which is one of the major concerns of this disease.”
Ewing’s sarcoma: segmentation analysis
This market research report segments the Ewing’s sarcoma market based on therapies employed (monotherapy and combination therapy), RoA (intravenous, oral, intradermal, intratumoral, subcutaneous, and undisclosed), therapeutic modalities (small molecule, monoclonal antibody, and vaccine), MoA (VEGF inhibitor, IGF-1R inhibitor, tubulin polymerization, CD99 inhibitor, others, and undisclosed), drugs under development (phase I, phase I/II, phase II, pre-clinical, phase III, and discovery), and recruitment status (recruiting, active not recruiting, not yet recruiting, completed, and unknown). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age Recruitment volume
Key CompaniesType of players Company Overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180709005771/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH ONCOLOGY GENERAL HEALTH
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/09/2018 02:13 PM/DISC: 07/09/2018 02:13 PM